DCC (OTCMKTS:DCCPF – Get Rating) and Better Therapeutics (NASDAQ:BTTX – Get Rating) are both business services companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, valuation, dividends, profitability and analyst recommendations.
Insider and Institutional Ownership
15.0% of Better Therapeutics shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
This is a breakdown of recent recommendations and price targets for DCC and Better Therapeutics, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Better Therapeutics has a consensus target price of $15.00, indicating a potential upside of 584.93%. Given Better Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Better Therapeutics is more favorable than DCC.
Valuation and Earnings
This table compares DCC and Better Therapeutics’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|DCC||$24.23 billion||0.28||$382.83 million||N/A||N/A|
|Better Therapeutics||$10,000.00||5,169.93||-$40.33 million||N/A||N/A|
DCC has higher revenue and earnings than Better Therapeutics.
This table compares DCC and Better Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk & Volatility
DCC has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500. Comparatively, Better Therapeutics has a beta of 1.66, suggesting that its stock price is 66% more volatile than the S&P 500.
DCC Company Profile (Get Rating)
DCC plc provides sales, marketing, and support services worldwide. The company's DCC LPG segment sells and markets liquefied petroleum gas (LPG), refrigerants, and natural gas. This segment serves approximately 0.9 million customers. Its DCC Retail & Oil segment markets, sells, and retails transport and commercial fuels, heating oils, and related products and services; operates retail petrol stations; resells fuel cards; distributes oil; and provides inbound logistics, storage and filling, and outbound logistics services. This segment serves domestic, agricultural, commercial/industrial, forecourt, aviation, and marine customers. The company's DCC Healthcare segment offers products and services to healthcare providers, and health and beauty brand owners; outsourced contract manufacturing services to the health and beauty sector; nutrition products, such as vitamins and health supplements; beauty products; and product development, formulation, manufacturing, and packaging services. In addition, this segment procures and sells exempt medicinal products. Its DCC Technology segment distributes consumer technology products, including smart home products, gaming consoles, peripherals and software, wearable technology, and accessories; business and enterprise technology products, such as tablets, notebooks, and PCs; networking and security products; communication products comprising smartphones, feature phones, accessories, and unified communication products; and servers and storage products, audio visual products, printers, peripherals, cables and connectors, and consumables to retailers, resellers, and integrators. It also provides supply chain services. DCC plc was founded in 1976 and is headquartered in Dublin, Ireland.
Better Therapeutics Company Profile (Get Rating)
Better Therapeutics, Inc. engages in developing software-based prescription digital therapeutics (PDT) platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Its lead product candidate in development is BT-001, an investigational PDT platform that uses digitally delivered Nutritional Cognitive Behavioral Therapy to treat type 2 diabetes. The company's products under development also include BT-002, a PDT that help patients with hypertension improve their blood pressure; and BT-003, a PDT that help patients with hyperlipidemia enhance cholesterol levels. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.
Receive News & Ratings for DCC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DCC and related companies with MarketBeat.com's FREE daily email newsletter.